Roche's tiragolumab flops in another Phase III lung cancer trial
Roche's immune checkpoint inhibitor tiragolumab, in combination with Tecentriq, failed to meet the primary endpoint of overall survival in the Phase III SKYSCRAPER-01 trial for lung cancer.